NCM
KZR

Nantahala Capital Management’s Kezar Life Sciences KZR Stock Holding History

Nantahala Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-276,754
Closed -$1.74M – 166
2025
Q4 		$1.74M Buy
+276,754
New +$1.61M 0.06% 133

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Nantahala Capital Management's KZR Position: Q1 2026 in Review

Nantahala Capital Management sold out of Kezar Life Sciences (KZR) in Q1 2026, closing a stake of 276,754 shares — an estimated $1.74M sold.

Nantahala Capital Management first reported a position in KZR in Q4 2025 and held it in 1 quarter. The position peaked at $1.74M in Q4 2025. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Nantahala Capital Management reported no remaining Kezar Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Nantahala Capital Management sold 276,754 Kezar Life Sciences shares in Q1 2026, an estimated $1.74M.
  • Nantahala Capital Management first reported a position in Kezar Life Sciences in Q4 2025 and held it in 1 quarter.
  • Nantahala Capital Management's Kezar Life Sciences position peaked at $1.74M in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.